Clinical Trials Logo
  1. Home
  2. Leiomyosarcoma
  3. NCT05427461

Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2 — SAMHY2  

Leiomyosarcoma Clinical Trial

Official title:
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2

Clinical Trial Summary

Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution of this rate over time. The study will be conducted on a population of patients with leiomyosarcoma and treated in the context of routine care. 20 patients will be included: - 10 patients with localized disease. - 10 patients with metastatic disease. For each included patient, blood samples will be collected during baseline visit and up to 24 months after inclusion.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05427461
Study type Interventional
Source Institut Claudius Regaud
Contact Thibaud VALENTIN
Phone 05 31 15 51 70
Email valentin.thibaud@iuct-oncopole.fr
Status Recruiting
Phase N/A
Start date January 13, 2023
Completion date July 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04535271 - Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma Phase 2
Recruiting NCT06088290 - Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma Phase 2/Phase 3
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Terminated NCT02940041 - Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
Completed NCT01442662 - Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine Phase 2
Completed NCT00062868 - LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Phase 1
Recruiting NCT04214457 - Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
Active, not recruiting NCT04420975 - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Phase 1
Terminated NCT04099277 - A Study of LY3435151 in Participants With Solid Tumors Phase 1
Not yet recruiting NCT05548179 - Exploring Clinical Trial Experiences of People With Leiomyosarcoma
Recruiting NCT02983539 - Detection of Circulating Tumor Cells in Patients With Sarcomas
Completed NCT00093080 - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Phase 2
Active, not recruiting NCT04624178 - A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Phase 2
Terminated NCT03959033 - Patient Reported Outcome Measures (PROMs) With Trabectedin
Recruiting NCT02275286 - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Phase 1/Phase 2
Active, not recruiting NCT01956084 - Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma Phase 1
Completed NCT01426633 - Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas Phase 1
Completed NCT00400569 - Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT05080790 - Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma Phase 2